ATE438096T1 - Hla-e bindung zu cd94/nkg2+ zellen - Google Patents

Hla-e bindung zu cd94/nkg2+ zellen

Info

Publication number
ATE438096T1
ATE438096T1 AT98959027T AT98959027T ATE438096T1 AT E438096 T1 ATE438096 T1 AT E438096T1 AT 98959027 T AT98959027 T AT 98959027T AT 98959027 T AT98959027 T AT 98959027T AT E438096 T1 ATE438096 T1 AT E438096T1
Authority
AT
Austria
Prior art keywords
cells
nkg2
hla
binding
inactivation
Prior art date
Application number
AT98959027T
Other languages
German (de)
English (en)
Inventor
Veronique Braud
David Allan
Graham Ogg
Christopher O'callaghan
Andrew Mcmichael
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE438096T1 publication Critical patent/ATE438096T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
AT98959027T 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen ATE438096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding
PCT/GB1998/003686 WO1999028748A2 (en) 1997-12-04 1998-12-04 Hla-e binding

Publications (1)

Publication Number Publication Date
ATE438096T1 true ATE438096T1 (de) 2009-08-15

Family

ID=10823165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959027T ATE438096T1 (de) 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen

Country Status (7)

Country Link
US (3) US7410767B1 (cg-RX-API-DMAC7.html)
EP (2) EP1036327B1 (cg-RX-API-DMAC7.html)
JP (4) JP4336451B2 (cg-RX-API-DMAC7.html)
AT (1) ATE438096T1 (cg-RX-API-DMAC7.html)
DE (1) DE69841020D1 (cg-RX-API-DMAC7.html)
GB (1) GB9725764D0 (cg-RX-API-DMAC7.html)
WO (1) WO1999028748A2 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
CA2456196A1 (en) * 2001-07-31 2003-02-13 Karl Petter Soderstrom Compositions and methods for modulation of immune responses
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
ATE405591T1 (de) * 2003-08-26 2008-09-15 Univ Danmarks Tekniske Kontinuierliches verfahren zur anordnung von makromolekulären substanzen und die anschliessende aufnahme und isolierung einer makromolekulären anordnung, sowie ein für dieses verfahren geeignetes system
WO2005111624A2 (en) * 2004-05-07 2005-11-24 Beckman Coulter, Inc. Mhc bridging system for detecting ctl-mediated lysis of antigen presenting cells
WO2006009838A2 (en) 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
HUE026107T2 (en) 2004-12-28 2016-05-30 Innate Pharma Monoclonal antibody to NKG2A
ES2385754T3 (es) * 2006-06-22 2012-07-31 Novo Nordisk A/S Receptores heterodiméricos solubles y usos de estos
WO2008009545A1 (en) 2006-06-30 2008-01-24 Novo Nordisk A/S Anti-nkg2a antibodies and uses thereof
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
AU2012268939B2 (en) 2011-06-17 2017-05-04 Novo Nordisk A/S Selective elimination of erosive cells
WO2014037422A1 (en) 2012-09-04 2014-03-13 Inven2 As Selective and controlled expansion of educated nk cells
JP6433480B2 (ja) * 2013-03-12 2018-12-05 サンガモ セラピューティクス， インコーポレイテッド Ｈｌａを修飾するための方法および組成物
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
EP3811970A1 (en) * 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
US10857219B2 (en) * 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
DK3193929T3 (da) 2014-09-16 2019-08-19 Innate Pharma Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
JP6767362B2 (ja) 2014-09-16 2020-10-14 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． リンパ球における阻害経路の中和
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
SG10202006685XA (en) 2014-10-23 2020-08-28 Innate Pharma Treatment of Cancers Using Anti-NKG2A Agents
PL3405495T3 (pl) 2016-01-21 2021-10-11 Innate Pharma Neutralizacja szlaków inhibitorowych w limfocytach
CN110809580A (zh) * 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
AU2019219454A1 (en) * 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US20200399377A1 (en) * 2018-02-23 2020-12-24 Abexxa Biologics Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
SG11202104969RA (en) 2018-11-16 2021-06-29 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
CA3121128A1 (en) * 2018-12-02 2020-06-11 Fate Therapeutics, Inc. Immunotherapies using enhanced ipsc derived effector cells
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
JP2023543835A (ja) 2020-09-30 2023-10-18 ドレン バイオ， インコーポレイテッド 抗ｃｄ９４抗体及びその使用方法
EP4388012A4 (en) * 2021-08-20 2025-09-17 Univ Duke ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES
WO2024036303A2 (en) * 2022-08-11 2024-02-15 The Trustees Of The University Of Pennsylvania Universal t cells and compositions and methods of use thereof
WO2024206190A1 (en) * 2023-03-24 2024-10-03 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112486A (ja) * 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112485A (ja) * 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) * 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding

Also Published As

Publication number Publication date
GB9725764D0 (en) 1998-02-04
JP2010024233A (ja) 2010-02-04
JP2009106299A (ja) 2009-05-21
DE69841020D1 (de) 2009-09-10
JP4336451B2 (ja) 2009-09-30
US7410767B1 (en) 2008-08-12
EP1036327B1 (en) 2009-07-29
JP2002513541A (ja) 2002-05-14
US20080274475A1 (en) 2008-11-06
WO1999028748A3 (en) 1999-12-23
EP1036327A2 (en) 2000-09-20
US20150361180A1 (en) 2015-12-17
EP2144065A1 (en) 2010-01-13
JP5268828B2 (ja) 2013-08-21
JP2013081478A (ja) 2013-05-09
WO1999028748A2 (en) 1999-06-10
JP4437160B2 (ja) 2010-03-24

Similar Documents

Publication Publication Date Title
ATE438096T1 (de) Hla-e bindung zu cd94/nkg2+ zellen
AR003466A1 (es) Compuestos 14-hidroxi-2-desoxoparahercuamida b
DE3786407D1 (de) Nukleierungssystem fuer polyamide.
DE69728758D1 (de) Vorrichtung zur kopplung von übertragungselementen
EP1104303A4 (en) CARBOHYDRATES OR 2'-MODIFIED OLIGONUCLEOTIDS WITH ALTERNATING INTERNAL CLEOSIDE BINDINGS
DE69824545D1 (de) Vorrichtung zur abgabe von kabelbindern
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
DE69801898D1 (de) Vorrichtung zur isolierung von lastschwingungen
EP0893772A3 (en) System and method for device monitoring
DK0755370T3 (da) Insekticide gødningsblandinger
EA199900475A1 (ru) Получение растительных гелей
BR9804676A (pt) Processo para o teste de um dispositivo de embreagem automatizado.
AR015687A2 (es) Gen aislado que codifica acil transferasa
NL1009876A1 (nl) Synergistisch stabilisatormengsel op basis van polyalkyl-1-oxa-diazaspirodecaanverbindingen.
BR9910202A (pt) Sistema de substâncias
EA199800867A1 (ru) Соединения тетрагидробетакарболина
ES2186807T3 (es) Inhibidores de trombina.
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
BG100248A (bg) Инхибитори на скваленсинтетаза
DE50102625D1 (de) Verbindungen zur Bestimmung der Aktivität von Phospholipase A2
ES2179908T3 (es) Acidos sacarosamonocarboxilicos acilados.
DE69934188D1 (de) Vorrichtung zur Dämpfung von Drehmomentschwankungen
ATE277060T1 (de) 1,5-anhydro-d-fruktose substituiert mit einer hydrophoben gruppe zur verwendung als antioxidant und/oder emulgator
ATE239369T1 (de) Vorrichtung zum vertreiben von schädlingen
MX9804043A (es) Composiciones parasiticidas a base de polisiloxanos ciclicos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties